BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

520 related articles for article (PubMed ID: 17652060)

  • 1. Low dose gemcitabine plus cisplatin in a weekly-based regimen as salvage therapy for relapsed breast cancer after taxane-anthracycline-containing regimens.
    Sánchez-Escribano Morcuende R; Alés-Martínez JE; Aramburo González PM
    Clin Transl Oncol; 2007 Jul; 9(7):459-64. PubMed ID: 17652060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High efficacy of gemcitabine and cisplatin in patients with predominantly anthracycline- and taxane-pretreated metastatic breast cancer.
    Heinemann V; Stemmler HJ; Wohlrab A; Bosse D; Losem C; Kahlert S; Rauthe G
    Cancer Chemother Pharmacol; 2006 May; 57(5):640-6. PubMed ID: 16163537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biweekly administration of gemcitabine and cisplatin chemotherapy in patients with anthracycline and taxane-pretreated metastatic breast cancer.
    Tas F; Guney N; Derin D; Camlica H; Aydiner A; Topuz E
    Invest New Drugs; 2008 Aug; 26(4):363-8. PubMed ID: 18165864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine plus cisplatin (GC): a salvage regimen for advanced breast cancer patients who have failed anthracycline and/or taxane therapy.
    Chitapanarux I; Lorvidhaya V; Kamnerdsupaphon P; Tharavichitkul E; Trakultivakorn H; Somwangprasert A; Sumitsawan S; Srisukho S; Watcharachan K; Sukthomya V
    Gan To Kagaku Ryoho; 2006 Jun; 33(6):761-6. PubMed ID: 16770093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin plus gemcitabine chemotherapy in taxane/anthracycline-resistant metastatic breast cancer.
    Somali I; Alacacioglu A; Tarhan MO; Meydan N; Erten C; Usalp S; Yilmaz U
    Chemotherapy; 2009; 55(3):155-60. PubMed ID: 19390188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuous infusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with metastatic breast cancer (MBC) pretreated with anthracycline and taxanes.
    Kalbakis K; Kouroussis C; Kakolyris S; Mavroudis D; Souglakos J; Agelaki S; Vamvakas L; Christodoulakis M; Stylianou K; Georgoulias V
    Br J Cancer; 2001 Sep; 85(6):798-802. PubMed ID: 11556827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane.
    Modi S; Currie VE; Seidman AD; Bach AM; Panageas KS; Theodoulou M; Moasser MM; D'Andrea GM; Lake DE; Choi J; Norton L; Hudis CA
    Clin Breast Cancer; 2005 Apr; 6(1):55-60. PubMed ID: 15899073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The combination of gemcitabine and vinorelbine is an active regimen as second-line therapy in patients with metastatic breast cancer pretreated with taxanes and/or anthracyclines: a phase I-II study.
    Morabito A; Filippelli G; Palmeri S; Cascinu S; Ferraù F; Zagonel V; Gattuso D; Catalano V; Capaccetti B; Franciosi V; Accurso V; Scinto F; Gasparini G
    Breast Cancer Res Treat; 2003 Mar; 78(1):29-36. PubMed ID: 12611454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gefitinib in combination with gemcitabine and vinorelbine in patients with metastatic breast cancer pre-treated with taxane and anthracycline chemotherapy: a phase I/II trial.
    Gioulbasanis I; Saridaki Z; Kalykaki A; Vamvakas L; Kalbakis K; Ignatiadis M; Amarantidis K; Kakolyris S; Georgoulias V; Mavroudis D
    Anticancer Res; 2008; 28(5B):3019-25. PubMed ID: 19031950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine/capecitabine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
    Andres R; Mayordomo JI; Lara R; Lastra R; Ortega E; Polo E; Lambea J; Isla D; Saenz-Cusi A; Escudero P; Tres A
    Clin Breast Cancer; 2005 Jun; 6(2):158-62. PubMed ID: 16001994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 2 study of the combination of gemcitabine and cisplatin in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines with/without taxanes.
    Kohail H; Shehata S; Mansour O; Gouda Y; Gaafar R; Hamid TA; El Nowieam S; Al Khodary A; El Zawahry H; Wareth AA; Halim IA; Taleb FA; Hamada E; Barsoum M; Abdullah M; Meshref M
    Hematol Oncol Stem Cell Ther; 2012; 5(1):42-8. PubMed ID: 22446614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter phase II trial of docetaxel plus gemcitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer.
    Karachaliou N; Kouroussis Ch; Papakotoulas P; Kalbakis K; Tryfonidis K; Vardakis N; Poppis E; Georgoulias V; Mavroudis D
    Cancer Chemother Pharmacol; 2012 May; 69(5):1345-52. PubMed ID: 22349809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
    Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine and cisplatin combination regimen in patients with anthracycline- and taxane-pretreated metastatic breast cancer.
    Wang T; Zhang S; Zeng M; Lu X; Shen G; Wu S; Song S; Jiang Z
    Med Oncol; 2012 Mar; 29(1):56-61. PubMed ID: 21264537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer.
    Dong N; Wu Y; Song C; Wang M; Jiao Y; Zhang S
    J BUON; 2020; 25(3):1348-1353. PubMed ID: 32862575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Capecitabine/cisplatin doublet in anthracycline and taxane pretreated and HER-2 negative metastatic breast carcinoma patients.
    Ozdemir N; Aksoy S; Sendur MA; Akinci MB; Yazici O; Budakoglu B; Abali H; Oksuzoglu B; Zengin N
    J BUON; 2013; 18(4):831-7. PubMed ID: 24344005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer.
    Pallis AG; Boukovinas I; Ardavanis A; Varthalitis I; Malamos N; Georgoulias V; Mavroudis D
    Ann Oncol; 2012 May; 23(5):1164-1169. PubMed ID: 21937705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane.
    Park JS; Jeung HC; Rha SY; Ahn JB; Kang B; Chon HJ; Hong MH; Lim S; Yang WI; Nam CM; Chung HC
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):799-808. PubMed ID: 25107569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer.
    Karachaliou N; Ziras N; Syrigos K; Tryfonidis K; Papadimitraki E; Kontopodis E; Bozionelou V; Kalykaki A; Georgoulias V; Mavroudis D
    Cancer Chemother Pharmacol; 2012 Jul; 70(1):169-76. PubMed ID: 22669571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes.
    Awada A; Biganzoli L; Cufer T; Beex L; Lohrisch C; Batter V; Hamilton A; Nooij M; Piccart M
    Eur J Cancer; 2002 Apr; 38(6):773-8. PubMed ID: 11937310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.